Bloomage Biotech(SH:688363) Xin Lang Cai Jing·2025-08-27 06:22Core Viewpoint - Huaxi Biological has shown a significant stock price increase this year, with a 16.63% rise, indicating positive market sentiment despite recent financial challenges [1][2]. Company Overview - Huaxi Biological Technology Co., Ltd. was established on January 3, 2000, and went public on November 6, 2019. The company is located in Jinan, Shandong Province, and specializes in microbial fermentation and cross-linking technology platforms [1]. - The company has developed a full industry chain business system that includes raw materials, medical terminal products, functional skincare products, and functional foods, serving global pharmaceutical, cosmetic, food manufacturing enterprises, medical institutions, and end-users [1]. Business Performance - For the first half of 2025, Huaxi Biological reported a revenue of 2.261 billion yuan, a year-on-year decrease of 19.57%, and a net profit attributable to shareholders of 221 million yuan, down 35.38% year-on-year [2]. - The company's main business revenue composition includes: 47.84% from skin science innovation transformation, 26.80% from medical terminal products, 23.02% from raw materials, and 2.17% from other sources [1]. Shareholder Information - As of July 31, 2025, the number of Huaxi Biological shareholders increased to 32,500, up 1.78% from the previous period, while the average circulating shares per person decreased by 1.75% to 14,799 shares [2]. - The company has distributed a total of 1.138 billion yuan in dividends since its A-share listing, with 528 million yuan distributed over the past three years [3]. Institutional Holdings - As of June 30, 2025, major institutional shareholders include Huaxia SSE Sci-Tech Innovation Board 50 ETF, E Fund SSE Sci-Tech Innovation Board 50 ETF, and Huabao CSI Medical ETF, with varying changes in their holdings [3].